The company said that Indomethacin for injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750g when after 48 hours usual medical management is ineffective.
This product is AP rated and is equivalent to Indocin by Lundbeck.
David Gaugh, vice president and general manager of Bedford Laboratories, said: “We are very excited and pleased to announce the launch of this critical product. The release of this product to the market place is very timely, given that the innovator product is currently on long-term backorder. This is a great milestone for Bedford Laboratories and we are very proud to add this product to our growing portfolio.”
Bedford Laboratories, headquartered in Bedford, Ohio, a division of Ben Venue Laboratories, supplies to US and International markets with multisource and specialty injectable products offering a range of multisource injectables across multiple therapeutic classes.